Patents by Inventor Brian Jeffrey Wenzel
Brian Jeffrey Wenzel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9687656Abstract: Provided herein are implantable systems, and methods for use therewith, for monitoring a patient's arterial blood pressure while a patient's heart is being paced. A signal (e.g., PPG or IPG signal) indicative of changes in arterial blood volume remote from the patient's heart is obtained using a sensor or electrodes that are implanted remote from the patient's heart. One or more metrics indicative of pulse arrival time (PAT) are determined, where each metric can be determined by determining a time from a paced cardiac event to one or more predetermined features of the signal indicative of changes in arterial blood volume. Based on at the metric(s) indicative of PAT, arterial blood pressure is estimated, which can include determining values indicative of systolic blood pressure, diastolic blood pressure, pulse pressure and/or mean arterial blood pressure, and/or changes in such values.Type: GrantFiled: December 14, 2009Date of Patent: June 27, 2017Assignee: Pacesetter, Inc.Inventors: Brian Jeffrey Wenzel, Timothy A. Fayram, Allen J. Keel, Edward Karst, Wenbo Hou, Taraneh Ghaffari Farazi
-
Patent number: 9282895Abstract: In an implantable medical device for monitoring glucose concentration in the blood, a blood-glucose concentration analysis is performed using correlations of blood-glucose concentration with measures of metabolic oxygen consumption including oxymetric, and/or temperature. Analysis of electrocardiographic data is used in a parallel method to detect and/or confirm the onset and/or existence and/or extent of hypoglycemia and/or hyperglycemia. Blood-glucose concentration calculation is enhanced by using the combination of the oxygen metabolism analysis and electrocardiographic analysis.Type: GrantFiled: December 10, 2013Date of Patent: March 15, 2016Assignee: Pacesetter, Inc.Inventors: Brian Jeffrey Wenzel, Taraneh Ghaffari Farazi, Euljoon Park, Eric Falkenberg, Michael E. Benser
-
Patent number: 9162065Abstract: In specific embodiments, a method for estimating central arterial blood pressure (CBP), comprises determining a time t1 from a predetermined feature of a signal indicative of electrical activity to a predetermined feature of one of a first and second signals, the time t1 being a first pulse arrival time (PAT1) indicative of how long it takes a pulse wave to travel from the aorta to one of a first and second sites, determining a time t2, the time t2 being a second pulse arrival time (PAT2) indicative of how long it takes a pulse wave to travel from the aorta to the other of the first and second sites, and (f) estimating the patient's central arterial blood pressure (CBP) based on the first pulse arrival time (PAT1) and the second pulse arrival time (PAT2).Type: GrantFiled: February 6, 2015Date of Patent: October 20, 2015Assignee: PACESETTER, INC.Inventors: Edward Karst, Brian Jeffrey Wenzel, Timothy A. Fayram, Allen Keel, Wenbo Hou, Taraneh Ghaffari Farazi, Jong Gill
-
Patent number: 9113789Abstract: Techniques are provided for estimating electrical conduction delays with the heart of a patient based on measured immittance values. In one example, impedance or admittance values are measured within the heart of a patient by a pacemaker or other implantable medical device, then used by the device to estimate cardiac electrical conduction delays. A first set of predetermined conversion factors may be used to convert the measured immittance values into conduction delay values. In some examples, the device then uses the estimated conduction delay values to estimate LAP or other cardiac pressure values. A second set of predetermined conversion factors may be used to convert the estimated conduction delays into pressure values. Techniques are also described for adaptively adjusting pacing parameters based on estimated LAP.Type: GrantFiled: May 31, 2012Date of Patent: August 25, 2015Assignee: Pacesetter, Inc.Inventors: Brian Jeffrey Wenzel, Dorin Panescu, Mihir Naware, Jeffery Siou
-
Publication number: 20150151130Abstract: In specific embodiments, a method for estimating central arterial blood pressure (CBP), comprises determining a time t1 from a predetermined feature of a signal indicative of electrical activity to a predetermined feature of one of a first and second signals, the time t1 being a first pulse arrival time (PAT1) indicative of how long it takes a pulse wave to travel from the aorta to one of a first and second sites, determining a time t2, the time t2 being a second pulse arrival time (PAT2) indicative of how long it takes a pulse wave to travel from the aorta to the other of the first and second sites, and (f) estimating the patient's central arterial blood pressure (CBP) based on the first pulse arrival time (PAT1) and the second pulse arrival time (PAT2).Type: ApplicationFiled: February 6, 2015Publication date: June 4, 2015Inventors: Edward Karst, Brian Jeffrey Wenzel, Timothy A. Fayram, Allen Keel, Wenbo Hou, Taraneh Ghaffari Farazi, Jong Gill
-
Patent number: 9002450Abstract: Techniques are provided for use with an implantable medical device for assessing left ventricular (LV) sphericity and atrial dimensional extent based on impedance measurements for the purposes of detecting and tracking heart failure and related conditions such as volume overload or mitral regurgitation. In some examples described herein, various short-axis and long-axis impedance vectors are exploited that pass through portions of the LV for the purposes of assessing LV sphericity. In other examples, impedance measurements taken along a vector between a right atrial (RA) ring electrode and an LV electrode implanted near the atrioventricular (AV) groove are exploited to assess LA extent, biatrial extent or mitral annular diameter. The assessment techniques can be employed alone or in conjunction with other heart failure detection techniques, such as those based on left atrial pressure (LAP.Type: GrantFiled: December 21, 2010Date of Patent: April 7, 2015Assignee: Pacesetter, Inc.Inventors: Stuart Rosenberg, Yelena Nabutovsky, Cecilia Qin Xi, Jong Gill, Kyungmoo Ryu, Brian Jeffrey Wenzel, William Hsu
-
Patent number: 8843197Abstract: A method for trending heart failure measures cardiogenic impedance (CI) and obtains signals representing estimates for or direct measurements of at least one of cardiac volume and pressure of the heart when the CI measurements were obtained. The method identifies correction factors based on the signals and applies the correction factors to the contractility estimates. A system for trending heart failure includes a contractility module to determine contractility estimates from CI measurements taken along at least a first vector through a heart, and a collection module to receive signals representing estimates for or direct measurements of at least one of cardiac volume and pressure of the heart when the CI measurements were obtained. The system further includes a factor module to identify correction factors based on the signals and a correction module to apply the correction factors to the contractility estimates.Type: GrantFiled: March 16, 2011Date of Patent: September 23, 2014Assignee: Pacesetter, Inc.Inventors: Stuart Rosenberg, Cecilia Qin Xi, Jong Gill, Brian Jeffrey Wenzel, Yelena Nabutovsky, William Hsu
-
Publication number: 20140221771Abstract: In an implantable medical device for monitoring glucose concentration in the blood, a blood-glucose concentration analysis is performed using correlations of blood-glucose concentration with measures of metabolic oxygen consumption including oxymetric, and/or temperature. Analysis of electrocardiographic data is used in a parallel method to detect and/or confirm the onset and/or existence and/or extent of hypoglycemia and/or hyperglycemia. Blood-glucose concentration calculation is enhanced by using the combination of the oxygen metabolism analysis and electrocardiographic analysis.Type: ApplicationFiled: December 10, 2013Publication date: August 7, 2014Applicant: Pacesetter, IncInventors: Brian Jeffrey Wenzel, Taraneh Ghaffari Farazi, Euljoon Park, Eric Falkenberg, Michael E. Benser
-
Patent number: 8798724Abstract: Methods and apparatuses for monitoring, with improved specificity, occurrences of episodes relating to disorders that are known to affect T-wave morphology. T-wave variability is monitored. When T-wave variability, or a change therein, exceeds a corresponding threshold for a specific period of time, monitoring for a specific change in T-wave morphology that is known to be indicative of episodes relating to a disorder may be triggered.Type: GrantFiled: March 28, 2012Date of Patent: August 5, 2014Assignee: PaceSetter, Inc.Inventors: Taraneh Ghaffari Farazi, Rupinder Bharmi, Brian Jeffrey Wenzel
-
Patent number: 8630692Abstract: In an implantable medical device for monitoring glucose concentration in the blood, a blood-glucose concentration analysis is performed using correlations of blood-glucose concentration with measures of metabolic oxygen consumption including oxymetric, and/or temperature. Analysis of electrocardiographic data is used in a parallel method to detect and/or confirm the onset and/or existence and/or extent of hypoglycemia and/or hyperglycemia. Blood-glucose concentration calculation is enhanced by using the combination of the oxygen metabolism analysis and electrocardiographic analysis.Type: GrantFiled: April 30, 2009Date of Patent: January 14, 2014Assignee: Pacesetter, Inc.Inventors: Brian Jeffrey Wenzel, Taraneh Ghaffari Farazi, Euljoon Park, Eric Falkenberg, Michael E. Benser
-
Patent number: 8571642Abstract: Provided herein are implantable systems, and methods for use therewith, for monitoring a patient's pre-ejection interval (PEI). A signal indicative of cardiac electrical activity and a signal indicative of changes in arterial blood volume are obtained. One or more predetermined features of the signal indicative of cardiac electrical activity and the signal indicative of changes in arterial blood volume are detected. The patient's PEI is determined by determining an interval between the predetermined feature of the signal indicative of cardiac electrical activity and the predetermined feature of the signal indicative of changes in arterial blood volume.Type: GrantFiled: September 14, 2010Date of Patent: October 29, 2013Assignee: Pacesetter, Inc.Inventors: Jong Gill, Brian Jeffrey Wenzel, Allen Keel, Wenbo Hou, Edward Karst, Taraneh G. Farazi
-
Patent number: 8517941Abstract: An implantable medical device, implantable cardiac stimulation device, implantable defibrillator or pacemaker provides continuous monitoring of blood-glucose concentration in the blood of a patient. Blood-glucose concentration and blood-glucose concentration trends are calculated by measuring changes in the hematocrit of the patient. An external blood-glucose monitor may be used to provide blood-glucose calibration values to the implantable device to enhance accuracy of blood-glucose concentration values. The implantable device compares the blood-glucose concentration and/or concentration trends with acceptable limits and generates appropriate warning signals. The implantable device may optionally control one or more therapeutic devices to maintain blood-glucose concentration within an acceptable range. The enhanced control of blood-glucose concentration reduces the risk of arrhythmia and enhances the effectiveness of cardiac pacing and/or defibrillation.Type: GrantFiled: October 23, 2007Date of Patent: August 27, 2013Assignee: Pacesetter, Inc.Inventor: Brian Jeffrey Wenzel
-
Patent number: 8504152Abstract: Techniques are provided for estimating left atrial pressure (LAP) or other cardiac performance parameters based on measured conduction delays. In particular, LAP is estimated based interventricular conduction delays. Predetermined conversion factors stored within the device are used to convert the various the conduction delays into LAP values or other appropriate cardiac performance parameters. The conversion factors may be, for example, slope and baseline values derived during an initial calibration procedure performed by an external system, such as an external programmer. In some examples, the slope and baseline values may be periodically re-calibrated by the implantable device itself. Techniques are also described for adaptively adjusting pacing parameters based on estimated LAP or other cardiac performance parameters. Still further, techniques are described for estimating conduction delays based on impedance or admittance values and for tracking heart failure therefrom.Type: GrantFiled: July 18, 2007Date of Patent: August 6, 2013Assignee: Pacesetter, Inc.Inventors: Brian Jeffrey Wenzel, Dan E. Gutfinger, Mihir Naware, Xiaoyi Min, Jeffery Siou, Anders Bjorling, Dorin Panescu
-
Patent number: 8504153Abstract: Techniques are provided for estimating left atrial pressure (LAP) or other cardiac performance parameters based on measured conduction delays. In particular, LAP is estimated based interventricular conduction delays. Predetermined conversion factors stored within the device are used to convert the various the conduction delays into LAP values or other appropriate cardiac performance parameters. The conversion factors may be, for example, slope and baseline values derived during an initial calibration procedure performed by an external system, such as an external programmer. In some examples, the slope and baseline values may be periodically re-calibrated by the implantable device itself. Techniques are also described for adaptively adjusting pacing parameters based on estimated LAP or other cardiac performance parameters. Still further, techniques are described for estimating conduction delays based on impedance or admittance values and for tracking heart failure therefrom.Type: GrantFiled: July 18, 2007Date of Patent: August 6, 2013Assignee: Pacesetter, Inc.Inventors: Brian Jeffrey Wenzel, Dan E. Gutfinger, Mihir Naware, Xiaoyi Min, Jeffery Siou, Anders Bjorling, Dorin Panescu
-
Patent number: 8478403Abstract: Embodiments of the present invention are directed to implantable systems, and methods for use therewith, that monitor and modify a patient's arterial blood pressure without requiring an intravascular pressure transducer. In accordance with an embodiment, for each of a plurality of periods of time, there is a determination one or more metrics indicative of pulse arrival time (PAT), each of which are indicative of how long it takes for the left ventricle to generate a pressure pulsation that travels from the patient's aorta to a location remote from the patient's aorta. Based on the one or more metrics indicative of PAT, the patient's arterial blood pressure is estimated. Changes in the arterial blood pressure are monitored over time. Additionally, the patient's arterial blood pressure can be modified by initiating and/or adjusting pacing and/or other therapy based on the estimates of the patient's arterial blood pressure and/or monitored changes therein.Type: GrantFiled: February 23, 2011Date of Patent: July 2, 2013Assignee: Pacesetter, Inc.Inventors: Brian Jeffrey Wenzel, Michael E. Benser, Taraneh Ghaffari Farazi, Timothy A. Fayram, Edward Karst, Allen Keel, Wenbo Hou, Jong Gill
-
Publication number: 20130137999Abstract: Techniques are provided for estimating electrical conduction delays with the heart of a patient based on measured immittance values. In one example, impedance or admittance values are measured within the heart of a patient by a pacemaker or other implantable medical device, then used by the device to estimate cardiac electrical conduction delays. A first set of predetermined conversion factors may be used to convert the measured immittance values into conduction delay values. In some examples, the device then uses the estimated conduction delay values to estimate LAP or other cardiac pressure values. A second set of predetermined conversion factors may be used to convert the estimated conduction delays into pressure values. Techniques are also described for adaptively adjusting pacing parameters based on estimated LAP.Type: ApplicationFiled: May 31, 2012Publication date: May 30, 2013Inventors: Brian Jeffrey Wenzel, Dorin Panescu, Mihir Naware, Jeffery Siou
-
Patent number: 8428698Abstract: Implantable systems, and methods for use therewith, are provided for monitoring a patient's diastolic function and/or heart failure (HF) condition. A signal indicative of changes in arterial blood volume and a signal indicative of electrical activity of the patient's heart are obtained. Beginnings of diastolic periods can be detected based on a feature of the signal indicative of changes in arterial blood volume. Ends of the diastolic periods can be detected based on a feature of the signal indicative of electrical activity of the patient's heart, or on the signal indicative of changes in arterial blood volume. Diastolic periods (DPs), isovolumic relaxation times (IVRTs) and/or diastolic filling times (DiFTs) can be estimated based on the detected beginnings of the diastolic periods and detected ends of the diastolic periods. The patient's diastolic function and/or HF condition (and/or changes therein) can be monitored based on the estimates of DP, IVRT and/or DiFT.Type: GrantFiled: May 29, 2009Date of Patent: April 23, 2013Assignee: Pacesetter, Inc.Inventors: Allen J. Keel, Brian Jeffrey Wenzel, Edward Karst, Wenbo Hou, Taraneh Ghaffari Farazi
-
Patent number: 8326428Abstract: An exemplary includes acquiring an electroneurogram of the right carotid sinus nerve or the left carotid sinus nerve, analyzing the electroneurogram for at least one of chemosensory information and barosensory information and calling for one or more therapeutic actions based at least in part on the analyzing. Therapeutic actions may aim to treat conditions such as sleep apnea, an increase in metabolic demand, hypoglycemia, hypertension, renal failure, and congestive heart failure. Other exemplary methods, devices, systems, etc., are also disclosed.Type: GrantFiled: April 15, 2011Date of Patent: December 4, 2012Assignee: Pacesetter, Inc.Inventors: Brian Jeffrey Wenzel, Taraneh Ghaffari Farazi
-
Patent number: 8326429Abstract: An exemplary includes acquiring an electroneurogram of the right carotid sinus nerve or the left carotid sinus nerve, analyzing the electroneurogram for at least one of chemosensory information and barosensory information and calling for one or more therapeutic actions based at least in part on the analyzing. Therapeutic actions may aim to treat conditions such as sleep apnea, an increase in metabolic demand, hypoglycemia, hypertension, renal failure, and congestive heart failure. Other exemplary methods, devices, systems, etc., are also disclosed.Type: GrantFiled: April 15, 2011Date of Patent: December 4, 2012Assignee: Pacesetter, IncInventors: Brian Jeffrey Wenzel, Taraneh Ghaffari Farazi
-
Patent number: 8321017Abstract: Implantable systems, and methods for use therewith, enable the monitoring of a patient's electromechanical delay (EMD) and arterial blood pressure. Paced cardiac events are caused by delivering sufficient pacing stimulation to cause capture. A cardiogenic impedance (CI) signal, indicative of cardiac contractile activity in response to the pacing stimulation being delivered, is obtained. One or more predetermined features of the CI signal are detected, and a value indicative of the patient's EMD is determined by determining a time between a delivered pacing stimulation and at least one of the detected one or more features of the CI signal. The value indicative of EMD can be used to more accurately determine metrics indicative of pulse arrival time (PAT), which can be used to estimate arterial blood pressure.Type: GrantFiled: December 14, 2009Date of Patent: November 27, 2012Assignee: Pacesetter, Inc.Inventors: Brian Jeffrey Wenzel, Timothy A. Fayram, Allen J. Keel, Edward Karst, Wenbo Hou, Taraneh Ghaffari Farazi